Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3342830 in healthy adults
NCT02751424Phase 1Terminated
- Sponsor
- GSK
- Start
- Jun 2016
- Primary completion
- Feb 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3342830 in bacterial infection (4 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Event (AE) and Serious Adverse Event (SAE), Number of Participants With Abnormal Hematology Parameters as a Measure of Safety-Grade 3 or Higher and 4 more. Started Jun 2016; status: terminated.
02
Drugs
GSK3342830
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02751424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751424.